Clinical Trials Logo

Coronary Artery Bypass Graft clinical trials

View clinical trials related to Coronary Artery Bypass Graft.

Filter by:

NCT ID: NCT00463853 Withdrawn - Clinical trials for Coronary Arteriosclerosis

Stem Cell Therapy as Adjunct to Revascularization

STAR
Start date: August 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether it is safe to receive an injection of your own bone marrow adult stem cells (autologous BM-MNC) to your heart wall during coronary artery bypass graft (CABG).

NCT ID: NCT00327418 Completed - Clinical trials for Cerebrovascular Accident

CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events

CARDS
Start date: January 1997
Phase: Phase 4
Study type: Interventional

A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy, microalbuminuria, macroalbuminuria, or who currently smoke, but who do not have established corornary heart disease or other macrovascular disease.

NCT ID: NCT00048308 Completed - Clinical trials for Coronary Artery Bypass Graft

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Start date: January 2002
Phase: Phase 3
Study type: Interventional

During a heart bypass procedure, a substance called "complement" is released by the body. This complement causes inflammation, which can lead to side effects such as chest pain, heart attacks, heart failure, or impairment of memory, language and motor skills. The purpose of this study is to find out if the study drug (pexelizumab), which blocks complement release, can reduce such side effects and be taken safely.